



## Compass Therapeutics to Participate in the Cantor Fitzgerald Future of Oncology Symposium

March 28, 2023

BOSTON, March 28, 2023 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the Company will participate in the Cantor Fitzgerald Future of Oncology Symposium, which is taking place virtually on April 3 – 5, 2023.

### Presentation details:

**Date:** Tuesday, April 4

**Time:** 8:15 AM ET

### About Compass Therapeutics

Compass Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. Compass's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. Compass's pipeline of novel product candidates is designed to target multiple critical biological pathways required for an effective anti-tumor response. These include modulation of the microvasculature via angiogenesis-targeted agents, induction of a potent immune response via activators on effector cells in the tumor microenvironment, and alleviation of immunosuppressive mechanisms used by tumors to evade immune surveillance. Compass plans to advance its product candidates through clinical development as both standalone therapies and in combination with proprietary pipeline antibodies based on supportive clinical and nonclinical data. Compass was founded in 2014 and is headquartered in Boston, Massachusetts. For more information, visit the Compass Therapeutics, Inc. website at [www.compasstherapeutics.com](http://www.compasstherapeutics.com).

### Investor Contact

[ir@compasstherapeutics.com](mailto:ir@compasstherapeutics.com)

### Media Contact

Anna Gifford, Communications Manager

[media@compasstherapeutics.com](mailto:media@compasstherapeutics.com)

617-500-8099